Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

Summary

This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.

Timeline

Start

2025-06-19

Primary completion

2025-10-07

Completion

2025-10-07

Drugs

Indications